Literature DB >> 23079975

Association of MHC class-III gene polymorphisms with ER-positive breast cancer in Chinese Han population.

Q Pan1, Y Ning, L Z Chen, S Zhang, Z Z Liu, X X Yang, W Wei, H Wei, Q G Li, H N Yue, J X Wang.   

Abstract

Polymorphisms of the major histocompatibility complex (MHC) have been linked to many diseases, especially autoimmune disorders. Previous studies have shown that genetic variants in MHC class III are associated with breast cancer. To determine if there is an association between MHC class III and breast cancer risk in the Chinese Han population, we carried out a hospital-based case-control study in Guangdong and Jiangsu Provinces, including 216 histologically confirmed breast cancer patients and 216 healthy controls. Nine SNP markers distributed in the class III-coding region were detected using the Sequenom MassARRAY(®) iPLEX System. Deviation from Hardy-Weinberg equilibrium was observed for seven SNPs. There was no significant association between these seven SNP variants and breast cancer in these Chinese women (unconditional logistic regression analysis). However, chr6_31697494 at BAT2, one of the seven SNPs, was found to be significantly associated with both ER- and PR-positive breast cancer. In addition, both chr6_31911109 at C6orf48 and chr6_31975605 at ZBTB12, another two of the seven SNPs, show relevance with ER-positive breast cancer. In conclusion, this is the first evidence that genetic polymorphisms in the MHC class III region are significantly associated with ER-positive breast cancer in the Han Chinese population.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23079975     DOI: 10.4238/2012.September.17.1

Source DB:  PubMed          Journal:  Genet Mol Res        ISSN: 1676-5680


  6 in total

1.  Association Analysis of the MHC in Lupus Nephritis.

Authors:  Ricong Xu; Qibin Li; Rongjun Liu; Juan Shen; Ming Li; Minghui Zhao; Meng Wang; Qijun Liao; Haiping Mao; Zhijian Li; Na Zhou; Peiran Yin; Yue Li; Xueqing Tang; Tian Wu; Zhong Zhong; Yan Wang; Zhen Ai; Ou Wang; Nan Chen; Xiaoqin Yang; Junbin Fang; Ping Fu; Jieruo Gu; Kun Ye; Jian Chen; Lie Dai; Huafeng Liu; Zhangsuo Liu; Yunhua Liao; Jianxin Wan; Guohua Ding; Jinghong Zhao; Hao Zhang; Shuxia Fu; Liangdan Sun; Xuejun Zhang; Huanming Yang; Jian Wang; Jun Wang; Jianjun Liu; Yingrui Li; Xueqing Yu
Journal:  J Am Soc Nephrol       Date:  2017-07-28       Impact factor: 10.121

2.  Heterogeneity of Breast Cancer Associations with Common Genetic Variants in FGFR2 according to the Intrinsic Subtypes in Southern Han Chinese Women.

Authors:  Huiying Liang; Xuexi Yang; Lujia Chen; Hong Li; Anna Zhu; Minying Sun; Haitao Wang; Ming Li
Journal:  Biomed Res Int       Date:  2015-09-03       Impact factor: 3.411

3.  A novel m6A reader Prrc2a controls oligodendroglial specification and myelination.

Authors:  Rong Wu; Ang Li; Baofa Sun; Jian-Guang Sun; Jinhua Zhang; Ting Zhang; Yusheng Chen; Yujie Xiao; Yuhao Gao; Qingyang Zhang; Jun Ma; Xin Yang; Yajin Liao; Wei-Yi Lai; Xiaolong Qi; Shukun Wang; Yousheng Shu; Hai-Lin Wang; Fengchao Wang; Yun-Gui Yang; Zengqiang Yuan
Journal:  Cell Res       Date:  2018-12-04       Impact factor: 25.617

4.  PRRC2A Promotes Hepatocellular Carcinoma Progression and Associates with Immune Infiltration.

Authors:  Xin Liu; Yize Zhang; Zenghan Wang; Liwen Liu; Guizhen Zhang; Jianhao Li; Zhigang Ren; Zihui Dong; Zujiang Yu
Journal:  J Hepatocell Carcinoma       Date:  2021-12-01

5.  Analysis of the SUMO2 Proteome during HSV-1 Infection.

Authors:  Elizabeth Sloan; Michael H Tatham; Marine Groslambert; Mandy Glass; Anne Orr; Ronald T Hay; Roger D Everett
Journal:  PLoS Pathog       Date:  2015-07-22       Impact factor: 7.464

6.  Associations of Genetic Variants at Nongenic Susceptibility Loci with Breast Cancer Risk and Heterogeneity by Tumor Subtype in Southern Han Chinese Women.

Authors:  Huiying Liang; Hong Li; Xuexi Yang; Lujia Chen; Anna Zhu; Minying Sun; Changsheng Ye; Ming Li
Journal:  Biomed Res Int       Date:  2016-02-28       Impact factor: 3.411

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.